A5003138198- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Ear Surgery and Otitis Media
- Clostridium difficile and Clostridium perfringens research
- Nasal Surgery and Airway Studies
- Gut microbiota and health
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Sinusitis and nasal conditions
- Autoimmune and Inflammatory Disorders
- Tracheal and airway disorders
- Diverticular Disease and Complications
- Diagnosis and treatment of tuberculosis
- Ear and Head Tumors
- Pharmaceutical studies and practices
- Nosocomial Infections in ICU
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Disaster Response and Management
- Pregnancy and Medication Impact
- Congenital Ear and Nasal Anomalies
- Mycobacterium research and diagnosis
- Pharmaceutical Economics and Policy
- Cytomegalovirus and herpesvirus research
Chang Gung Memorial Hospital
2017-2025
Taiwan Nurses Association
2024-2025
Chang Gung University
2025
Linkou Chang Gung Memorial Hospital
2025
Abstract Background Inflammatory bowel disease (IBD) primarily affects young people, but increasing evidence indicates a shift toward older age. Elderly-onset IBD has several unique features, including atypical presentations and higher risk for infections malignancies. However, no studies have compared the clinical outcomes analyzed persistence of different advanced therapies in elderly-onset patients. This study aims to address this gap. Methods In retrospective cohort study, we included...
Abstract Background While biologics have significantly improved outcomes in inflammatory bowel disease (IBD), remission rates refractory cases remain suboptimal. Advanced combination therapy (ACT) presents a potential strategy to overcome this therapeutic ceiling IBD. Upadacitinib (UPA), an oral selective Janus kinase inhibitor, offers rapid action and low immunogenicity, showing promise IBD management. However, no studies evaluated the safety efficacy of ACT combining UPA Asia. This...
Abstract Background Crohn’s disease (CD) is a progressive condition, and early treatment with infliximab combined an immunosuppressant within six months has been shown to improve clinical outcomes. However, the impact of ustekinumab (UST) use in biologic-naïve CD patients remains unclear. This study aims address this gap by evaluating outcomes UST intervention such patients. Methods In retrospective cohort study, we included treated UST, follow-up period at least months, from October 2020...
Abstract Background Obesity has emerged as a factor influencing outcomes in inflammatory bowel disease (IBD), yet its effect on the persistence of advanced biologic therapies, especially Asian populations, remains unclear. This study evaluates obesity’s impact clinical and treatment among Taiwanese IBD patients therapies. Methods retrospective cohort was conducted at Chang Gung Memorial Hospital, Taiwan, involving biologics between April 2017 October 2024. Patients were categorized by BMI...
Abstract Background Clostridioides difficile infection (CDI) is known to trigger acute flare-ups and worsen clinical outcomes in patients with inflammatory bowel disease (IBD). Increasing evidence suggests that co-infection Clostridium innocuum (CI), which resistant vancomycin, also contributes negative outcomes. However, CI often overlooked or misdiagnosed. No previous study has specifically examined the impact of IBD CDI. This aims address this gap. Methods retrospective cohort included...
Abstract Background Thromboembolism (TE) notably increase morbidity and mortality among inflammatory bowel disease (IBD) patients. Despite ECCO's 2024 guidelines advocating routine anticoagulant prophylaxis, its application in Asia remains inconsistent due to a lack of regional studies. This research investigates the incidence predictors TE during IBD-related hospitalizations Taiwan, aiming improve prevention strategies. Methods Our retrospective cohort study included 282 adult IBD patients,...
Abstract Background Clostridioides difficile infection (CDI) significantly exacerbates and worsens the prognosis of inflammatory bowel disease (IBD). While fecal microbiota transplantation (FMT) is recognized as a safe efficacious therapy for patients battling recurrent or refractory CDI, but comparative studies focusing on success rates in IBD non-IBD remain scarce. Our study aims to shed light this gap knowledge. Methods In retrospective cohort conducted at Chang Gung Memorial Hospital...
Abstract Background The prevalence of inflammatory bowel disease (IBD) has been rapidly increasing in Asia. Advanced therapies have significantly improved outcomes for moderate to severe cases IBD. With the expanding availability advanced therapies, selection most suitable treatment option become crucial. Among various factors, persistence holds paramount importance. We present first study Asia that compares real-world rates among IBD patients Taiwan. Methods In this retrospective cohort...
Abstract Background With the rise in biologic therapies to manage moderate severe inflammatory bowel disease (IBD), determining optimal treatment sequence has become crucial. This aids selection of next agent after prior exposure or unresponsiveness a previous regimen. Vedolizumab (VDZ) is gut-specific α4β7-integrin inhibitor recognized for its efficacy treating IBD. Yet, only few studies have assessed comparative effectiveness alternative biologics, such as ustekinumab (UST) and antitumor...
Abstract Background Crohn's Disease (CD) affects the entire gastrointestinal tract, predominantly involving terminal ileum and colon. However, incidence implications of upper tract involvement in CD are often underestimated underreported, especially Asian populations. This study provides a comprehensive evaluation clinical characteristics outcomes associated with UGI CD. Methods We conducted retrospective cohort at Chang Gung Memorial Hospital, Linkou, from January 2001 to June 2023,...
Abstract Background Advanced therapies (ATs) with different mechanisms of action and routes administration (RoA) are used for inflammatory bowel disease (IBD: Crohn’s [CD] ulcerative colitis [UC]), patients (pts) play an increasing role in the decision-making process.Pts’ preferences treatment attributes from 7 European countries have been reported previously; however, evidence non-European is lacking. Methods Adult pts CD or UC on ≥6 months Argentina, Australia, Brazil, Saudi Arabia Taiwan...
Abstract Background Clostridioides difficile (C. difficile) infection (CDI) increases the risks of hospitalization, colectomy, and mortality in inflammatory bowel disease (IBD). There has been no study comprehensively evaluating risk factors, clinical characteristics, outcomes CDI IBD. Methods In this retrospective cohort study, we enrolled hospitalized IBD patients with toxin A/B results for C. a medical center between April 2007 2021. They were divided into group control groups. The...
Abstract Background CMV colitis is associated with acute flare-up and poor prognosis in inflammatory bowel disease (IBD). However, few studies showed the clinical manifestations, risk factors, prognostic factors impact of anti-viral treatment IBD inpatients. Therefore, we aimed to comprehensively analyze these issues this largest cohort study Asia. Methods We retrospectively enrolled 118 patients, including 42 76 non-CMV colitis, confirmed by immunohistochemistry (IHC) staining from colonic...